crenauer

Cory Renauer

Cory is a long-term minded analyst mainly focused on the biotechnology and pharmaceuticals. He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. He's a husband and father that is always up for just about any outdoor activity. You can contact Cory on Twitter @coryrenauer

crenauer’s Activity

Wed Jul 23

NL

Article

crenauer published an article 4:00 PM

Why Biogen Idec Stock Is Firing on All Cylinders

Biogen Idec's latest earnings report is the envy of the industry with better than expected growth of its soon to be best-seller Tecfidera.

Tue Jul 22

NL

Article

crenauer published an article 4:28 PM

How Big Is This Risk for Isis Pharmaceuticals, inc. Stock?

While the poor initial reception to Isis Pharmaceutical's Kynamro is upsetting, its performance might be the least of the company’s worries.

Mon Jul 21

NL

Article

crenauer published an article 10:22 AM

Is this Exelixis Stock's Worst Nightmare?

Exelixis has a great lineup of promising oncology candidates, but will it be able to develop them?

Sun Jul 20

NL

Article

crenauer published an article 5:00 PM

Can Abbott Laboratories Stock Continue to Impress?

Better than expected quarterly results boosted shares of Abbott Labs. Can its growth strategy continue to impress?

Wed Jul 16

NL

Article

crenauer published an article 9:29 AM

Why Johnson & Johnson Keeps Defying Gravity

Find out how a company as large as Johnson & Johnson continues to post double-digit gains.

Mon Jul 14

NL

Article

crenauer published an article 3:38 PM

2 Reasons to Watch Bristol-Myers Squibb Co

Bristol-Myers Squibb is winning big in Japan, can they bring that success home?

Thu Jul 3

NL

Article

crenauer published an article 10:52 AM

Time to Buy Vertex Pharmaceuticals Inc?

Vertex's cystic fibrosis franchise is just getting started.

Wed Jun 4

NL

Article

crenauer published an article 11:20 AM

2 Reasons to Watch Amgen, Inc.

Two of Amgen's candidates look increasingly promising.

Fri May 30

NL

Article

crenauer published an article 4:14 PM

3 Reasons Celgene Is a Buy

From the near to long-term there are many chapters left in Celgene's growth story.

Tue May 27

NL

Article

crenauer published an article 3:14 PM

The 3 Biggest Biotech Wins of the Week

See who released the best clinical results during the week ending May 25.

Sat May 24

NL

Article

crenauer published an article 12:43 PM

3 Reasons to Put Gilead On Your Watchlist

Sovaldi is huge, but it isn't Gilead's only opportunity.

Wed May 21

NL

Article

crenauer published an article 1:45 PM

Why AstraZeneca plc Shareholders Should Be Furious

AstraZeneca's decision to gamble on an uncertain future is clearly irresponsible.

Tue May 20

NL

Article

crenauer published an article 6:30 PM

The Biggest Biotech Wins of the Week

See who released the best clinical results during the week ending May 18.

Fri May 9

NL

Article

crenauer published an article 12:27 AM

1 Biotech Refusing to Stick Its Neck Out

Can you expect Imbruvica sales to level off this year?

Mon May 5

NL

Article

crenauer published an article 3:55 PM

Can Bristol-Myers Squibb Make a Comeback in 2014?

Outstanding performance of current drugs might help investors forget about Bristol-Myers Squibb's impending patent losses.

NL

Article

crenauer published an article 9:12 AM

The Biggest Biotech Catastrophes of the Week

See which companies suffered the worst clinical setbacks in the week ending May 2.

Sun May 4

NL

Article

crenauer published an article 5:21 AM

Medtronic, Inc: Should You Buy This Dividend Aristocrat?

See why Medtronic might be able to increase dividends for another 25 years.

Tue Apr 29

NL

Article

crenauer published an article 9:10 AM

Abbott Laboratories or Johnson & Johnson: Which Dividend Aristocrat is a Better Buy?

See if Abbott Laboratories or Johnson & Johnson is best suited for your dividend portfolio.

Mon Apr 28

NL

Article

crenauer published an article 6:30 PM

Could Celgene Beat the Biotech Slide?

Celgene stock has slid more than 15% this year, that doesn't mean it isn't poised for success

NL

Article

crenauer published an article 9:01 AM

Clinical Winners and Losers: Spectrum Pharmaceuticals and Cytokinetics

Find out which biotech posted the best, and worst, clinical results last week.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 55.57
Player Rank 33351 out of 75062
Score 8.41
Score Change Today -35.22
Accuracy 53.52%
Active Picks 26
Total Picks 75
Best Pick GILD (+75.15)
Worst Pick NSPH (-97.90)
Average Score per Pick 0.11
Charms Earned 2
Highest Rated Favorite No Favorites Selected
Go to crenauer’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show crenauer’s 10 Latest Posts